Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases

被引：0
|
作者：
Palmedo, Holger [1 ]
Guhlke, Stefan [1 ]
Bender, Hans [1 ]
Sartor, Johannes [1 ]
Schoeneich, Georg [2 ]
Risse, Jörn [1 ]
Grünwald, Frank [1 ]
Knapp Jr., F.F. [3 ]
Biersack, Hans-Jürgen [1 ]
机构：
[1] Department of Nuclear Medicine, University of Bonn, Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany
[2] Department of Urology, University of Bonn, Germany
[3] Nuclear Medicine Group, Oak Ridge National Laboratory, (ORNL), Oak Ridge, TN, United States
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2000年 / 27卷 / 02期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Grading
引用
收藏
页码：123 / 130
相关论文
共 50 条
  • [31] Clinical benefit of routine application of Rhenium-188-HEDP in patients with painful bone metastases from prostate or breast cancer
    Lange, R.
    Overbeek, F.
    van den Berk, A. M.
    de Klerk, J. M. H.
    Pasker-de Jong, P. C. M.
    ter Heine, R.
    van der Westerlaken, M. M. L.
    Rodenburg, C. J.
    Hendrikse, N. H.
    Bloemendal, H. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S336 - S336
  • [32] Recalcitrant primary extramammary scrotal Paget disease in a patient with prostate cancer and May-Hegglin anomaly treated successfully with Rhenium-188 (188Re) brachytherapy
    Scotti, Biagio
    Corti, Barbara
    Castellucci, Paolo
    Viola, Costanza
    Vetrone, Luigia
    Venturi, Federico
    Baraldi, Carlotta
    Fanti, Stefano
    Dika, Emi
    JOURNAL OF DERMATOLOGY, 2025,
  • [33] Rhenium-188 as an alternative to iodine-131 for treatment of prostate cancer following tissue-specific sodium iodide symporter gene transfer
    Willhauck, M. J.
    Sharif Samani, B. R.
    Wolf, I
    FJ, Gildehaus
    Finke, M.
    Goke, B.
    Senekowitsch-Schmidtke, R.
    Morris, J. C.
    Spitzweg, C.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 : S59 - S60
  • [34] Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radio pharmaceutical rhenium-188-HEDP Clinical benefit in a real-world study
    Lange, Rogier
    Overbeek, Floor
    de Klerk, John M. H.
    Pasker-de Jong, Pieternel C. M.
    van den Berk, Alexandra M.
    ter Heine, Rob
    Rodenburg, Cees J.
    Kooistra, Anko
    Hendrikse, N. Harry
    Bloemendal, Haiko J.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (05): : 188 - 195
  • [35] Use of radiobiological indices to guide dose escalation of the prostate cancer patients
    Burman, C
    Happersett, L
    Kutcher, G
    Leibel, S
    Zelefsky, M
    Fuks, Z
    Ling, CC
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 194 - 194
  • [36] A Phase | Pharmacodynamic Dose Escalation Study of Steroid Sulphatase Inhibitor Irosustat in Patients With Prostate Cancer
    Denmeade, S.
    George, D.
    Liu, G.
    Peraire, C.
    Geniaux, A.
    Baton, F.
    Ali, T.
    Chetaille, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S499 - S499
  • [37] Prostate Cancer Dose Escalation Including Lymph Nodes: A Planning Study
    Wu, Q.
    Song, H.
    Salama, J.
    MEDICAL PHYSICS, 2014, 41 (06) : 397 - 397
  • [38] Dose dependent early effects of rhenium-188 on proliferation, migration and extracellular matrix synthesis of human arterial smooth muscle cells: An in vitro study
    Wiskirchen, J
    Dittmann, H
    Betsch, A
    Gebert, R
    Claussen, CD
    Duda, SH
    RADIOLOGY, 2000, 217 : 377 - 378
  • [39] CANCER OF PROSTATE WITH OSSEOUS METASTASES - PROLONGED PAIN RELIEF WITH VERY HIGH-DOSE EPIDURAL MORPHINE
    STAV, A
    OVADIA, L
    LANDAU, M
    WEKSLER, N
    STERNBERG, A
    WORLD JOURNAL OF UROLOGY, 1991, 9 (04) : 240 - 242
  • [40] Feasibility study of manual dose escalation method with normal tissue complication probability in radiation dose escalation for prostate cancer
    Yoo, Denis
    Min, Byung Jun
    Rah, C. J.
    Lee, Eric
    Park, Jeong Hoon
    Shin, Dongho
    Kim, Eun Ho
    JOURNAL OF THE KOREAN PHYSICAL SOCIETY, 2023, 82 (04) : 420 - 429
12345